Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 6 results for "Hcl Me U2"

Patent Issued for 1-Aryl-1-Hydroxy-2,3-Diamino-Propyl Amines, ...

Patent Issued for 1-Aryl-1-Hydroxy-2,3-Diamino-Propyl Amines, 1-Heteroaryl-1-Hydroxy-2,3-Diamino-Propyl Amines and Related Compounds Having Analgesic And/Or Immuno Stimulant Activity (USPTO 9399628) By a News Reporter-Staff News Editor at Cancer ... Pharmacy Choice, 3 weeks ago

Researchers Submit Patent Application, "Process of Preparing a Quinazoline Derivative", for Approval (USPTO 20160200688)

By a News Reporter-Staff News Editor at Drug Week From Washington, D.C., NewsRx journalists report that a patent application by the inventors Zhang, Xiaoheng (Changshu, CN); Lv, Xizhou (Changshu, CN), filed on June 10, 2014, was made available ...
 Pharmacy Choice3 weeks ago BRISTOL MYERS SQUIBB : Patent Issued for Methods for the Preparation of HIV Attachment Inhibitor Piperazine Prodrug Compound (USPTO 9394322)  4 Traders1 month ago

METATRON : to Introduce Anti-Dilutive Stock Dividend

/ Metatron (OTCPink: MRNJ) is pleased to announce today that, pursuant to a special meeting of the Board of Directors, it will propose a resolution to issue a convertible preferred stock dividend to all stockholders of record. The Company intends to ...
 4 Traders2 months ago Metatron to Introduce Anti-Dilutive Stock Dividend  Equities.com2 months ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less